Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio Inc (ACET)
:ACET
Holding ACET?
Track your performance easily
ACET Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $3.62
Previous CloseN/A
Volume197.46K
Average Volume (3M)547.15K
Market Cap
$75.78M
Enterprise Value-$53.05M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 12, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,400,960
10 Day Avg. Volume526,028
30 Day Avg. Volume547,147
Standard Deviation0.26
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)107.32
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.70
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-74.30
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$7.00Price Target Upside660.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Advances with Phase 1 Trial of ADI-270
PremiumCompany Announcements
Adicet Bio Clears Debts with Banc of California
PremiumCompany Announcements
Adicet Bio Reports Q3 2024 Results and Clinical ProgressPremiumCompany Announcements
Adicet Bio Advances Cancer and Autoimmune Trials
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAdicet announced that the first patient has been dosed in the multi-center, open-label Phase 1 clinical trial evaluating ADI-270.
Financial PositionAdicet has a solid cash position of $202.1MM.
Regulatory MilestonesADI-001 has been granted Fast Track Designation by the FDA for potential treatment of relapsed or refractory class III or class IV lupus nephritis.
Bears Say
Financial PerformanceFor FY24, the EPS estimate is being decreased, indicating potential financial challenges.
Market CompetitionThere is no confirmation yet that engineered gamma-delta T cells offer a superior therapeutic option over current standards.
Product DevelopmentThe company has discontinued enrollment for its lead program and currently has no clinical data available for new potential indications.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACET FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was $0.81 and its highest was $3.62 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $75.78M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Mar 12, 2025 which is in 53 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on Nov 06, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.341 by $0.001.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc does not currently pay dividends.
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -0.36.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 82,400,960 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.341. Following the earnings report the stock price went up 2.308%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Among the largest hedge funds holding Adicet Bio Inc’s share is RA Capital Management. It holds Adicet Bio Inc’s shares valued at 11M.
---
Adicet Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (660.87% Upside)
$7.00 (660.87% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 519.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.36%
12-Months-Change
Fundamentals
Return on Equity
-58.04%
Trailing 12-Months
Asset Growth
5.45%
Trailing 12-Months
Company Description
Adicet Bio Inc
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
ACET Stock 12 Month Forecast
Average Price Target
$7.00
▲(660.87% Upside)
Technical Analysis
Immatics
―
Intellia Therapeutics
―
Adaptimmune Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Allogene Therapeutics
―
Best Analysts Covering ACET
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-11.02%
reiterated a buy rating 4 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -11.02% per trade.
---